Detection of Circulating Tumor Cells and Evaluation of Epithelial-mesenchymal Transition Patterns of Circulating Tumor Cells in Ovarian Cancer

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Sep 12

PMID 36093536

Authors

Xiao-Xiang Jie

Meng Zhang

Ming Du

Qing-Qing Cai

Qing Cong

Cong-Jian Xu

Xiao-Yan Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Circulating tumor cells (CTCs) have considered to be promising liquid biopsy in cancer due to the intact information of whole cells and the potential to reflect micrometastasis. However, CTCs research are extremely limited in ovarian cancer, probably due to their rarity. The predictive value of CTCs and circulating tumor microemboli (CTM) in metastasis remains to be elucidated in ovarian cancer. This study tried to identify CTCs/CTM in ovarian cancer with considerably positive rate. To preliminarily identify the invasive capacity of CTCs/CTM, the epithelial-mesenchymal transition (EMT) patterns of CTCs/CTM was evaluated. Moreover, for comprehensive understanding of invasiveness of disseminated cells in ovarian cancer, EMT pattern of exfoliated tumor cells in ascites were also confirmed in this study.

Methods: Peripheral blood samples and ascites samples were collected from 22 ovarian cancer patients. The Microfiltration combined with morphological analysis was used to detect CTC single cells or cell clusters. Microfiltration combined with morphological analysis was applied in the CTC isolation and identification. EMT was evaluated by immunofluorescence via markers including vimentin and cytokeratin.

Results: Microfiltration combined with morphological analysis was introduced to detect CTCs/CTM with a positivity rate of 40.9% in ovarian cancer patients. The number of CTC varied from 1 to 8, with CTM number from 4 to 30. CTCs/CTM of all samples have experienced EMT process. Vimentin was expressed in all CTC samples and all tumor cells in ascites, while cytokeratin was expressed in 44.4% (4/9) of CTC samples. There were no significant differences of the clinical parameters between the CTC-positive and CTC-negative patients.

Conclusions: This study showed that both CTCs/CTM and detached tumor cells in ascites might have undergone complete or partial EMT in ovarian cancer. Moreover, microfiltration combined with cytomorphological analysis showed a considerable CTC detection rate.

Citing Articles

EFHD1 Activates SIK3 to Limit Colorectal Cancer Initiation and Progression via the Hippo Pathway.

Huang Q, Tang X, Gan C, Deng Q, Zhi S, Huang Q J Cancer. 2025; 16(4):1348-1362.

PMID: 39895792 PMC: 11786025. DOI: 10.7150/jca.103229.

Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.

Nie C, Shaw I, Chen C J Pharm Anal. 2024; 13(12):1429-1451.

PMID: 38223444 PMC: 10785256. DOI: 10.1016/j.jpha.2023.08.009.

Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.

Zhang H, Wang L, Wu H Front Oncol. 2024; 13:1276085.

PMID: 38169730 PMC: 10758434. DOI: 10.3389/fonc.2023.1276085.

Single-cell analysis technologies for cancer research: from tumor-specific single cell discovery to cancer therapy.

Chen S, Jiang W, Du Y, Yang M, Pan Y, Li H Front Genet. 2023; 14:1276959.

PMID: 37900181 PMC: 10602688. DOI: 10.3389/fgene.2023.1276959.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Zhang X, Li H, Yu X, Li S, Lei Z, Li C . Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker. Cell Physiol Biochem. 2018; 48(5):1983-1994. DOI: 10.1159/000492521. View

Liu P, Kang B, Wu Y, Sun J, Yen L, Fu T . Vimentin is a potential prognostic factor for tongue squamous cell carcinoma among five epithelial-mesenchymal transition-related proteins. PLoS One. 2017; 12(6):e0178581. PMC: 5453552. DOI: 10.1371/journal.pone.0178581. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Tamminga M, Andree K, Hiltermann T, Jayat M, Schuuring E, van den Bos H . Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch and ISET. Cancers (Basel). 2020; 12(4). PMC: 7226321. DOI: 10.3390/cancers12040896. View

Guo Y, Neoh K, Chang X, Sun Y, Cheng H, Ye X . Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget. 2018; 9(7):7522-7533. PMC: 5800921. DOI: 10.18632/oncotarget.23943. View

Asante D, Calapre L, Ziman M, Meniawy T, Gray E . Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Lett. 2019; 468:59-71. DOI: 10.1016/j.canlet.2019.10.014. View

de Wit S, van Dalum G, Lenferink A, Tibbe A, Hiltermann T, Groen H . The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep. 2015; 5:12270. PMC: 4505332. DOI: 10.1038/srep12270. View

Lheureux S, Braunstein M, Oza A . Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019; 69(4):280-304. DOI: 10.3322/caac.21559. View

10.

Dong P, Xiong Y, Watari H, Hanley S, Konno Y, Ihira K . MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer Res. 2016; 35(1):132. PMC: 5011787. DOI: 10.1186/s13046-016-0415-y. View

11.

Ning D, Cui K, Liu M, Ou Y, Wang Z, Zou B . Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer. Med Sci Monit. 2021; 27:e926565. PMC: 7802377. DOI: 10.12659/MSM.926565. View

12.

Wu S, Liu S, Liu Z, Huang J, Pu X, Li J . Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One. 2015; 10(4):e0123976. PMC: 4409386. DOI: 10.1371/journal.pone.0123976. View

13.

Marcucci F, Stassi G, De Maria R . Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov. 2016; 15(5):311-25. DOI: 10.1038/nrd.2015.13. View

14.

Elloul S, Vaksman O, Stavnes H, Trope C, Davidson B, Reich R . Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis. 2010; 27(3):161-72. DOI: 10.1007/s10585-010-9315-2. View

15.

Yi B, Kim T, Kim Y, Choi K . Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers. Int J Oncol. 2014; 46(1):272-80. DOI: 10.3892/ijo.2014.2695. View

16.

Kuhlmann J, Wimberger P, Bankfalvi A, Keller T, Scholer S, Aktas B . ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2014; 60(10):1282-9. DOI: 10.1373/clinchem.2014.224808. View

17.

Yang J, Ma J, Jin Y, Cheng S, Huang S, Zhang N . Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition. Sci Rep. 2021; 11(1):6540. PMC: 7985206. DOI: 10.1038/s41598-021-86122-4. View

18.

Li Y, Xu S, Li J, Han K, Pi H, Zheng L . Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis. 2013; 4:e831. PMC: 3824657. DOI: 10.1038/cddis.2013.347. View

19.

Hou J, Krebs M, Ward T, Sloane R, Priest L, Hughes A . Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011; 178(3):989-96. PMC: 3069884. DOI: 10.1016/j.ajpath.2010.12.003. View

20.

Chen J, Cao S, Cai Z, Zheng L, Wang Q . Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients. Cancer Biomark. 2017; 20(4):487-498. DOI: 10.3233/CBM-170315. View